Ras GTPases are activated by RasGEFs and inactivated by RasGAPs, which stimulate the hydrolysis of RasGTP to inactive RasGDP. GTPase-impairing somatic mutations in RAS genes, such as KRAS G12D , are among the most common oncogenic events in metastatic cancer. A different type of cancer Ras signal, driven by overexpression of the RasGEF RasGRP1 (Ras guanine nucleotide-releasing protein 1), was recently implicated in pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients and murine models, in which RasGRP1 T-ALLs expand in response to treatment with interleukins (ILs) 2, 7 and 9. Here, we demonstrate that IL-2/7/9 stimulation activates Erk and Akt pathways downstream of Ras in RasGRP1 T-ALL but not in normal thymocytes. In normal lymphocytes, RasGRP1 is recruited to the membrane by diacylglycerol (DAG) in a phospholipase C-γ (PLCγ)-dependent manner. Surprisingly, we find that leukemic RasGRP1-triggered Ras-Akt signals do not depend on acute activation of PLCγ to generate DAG but rely on baseline DAG levels instead. In agreement, using three distinct assays that measure different aspects of the RasGTP/GDP cycle, we established that overexpression of RasGRP1 in T-ALLs results in a constitutively high GTP-loading rate of Ras, which is constantly counterbalanced by hydrolysis of RasGTP. KRAS G12D T-ALLs do not show constitutive GTP loading of Ras. Thus, we reveal an entirely novel type of leukemogenic Ras signals that is based on a RasGRP1-driven increased in flux through the RasGTP/GDP cycle, which is mechanistically very different from KRAS G12D signals. Our studies highlight the dynamic balance between RasGEF and RasGAP in these T-ALLs and put forth a new model in which IL-2/7/9 decrease RasGAP activity.
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer associated with poor prognosis, especially after disease relapse (reviewed in Aifantis et al.
1
). The current line of treatment consists of cytotoxic chemotherapy with many side effects. Potential targeted treatment requires detailed understanding of the leukemogenic signals.
Despite being extremely aggressive in vivo, leukemic blasts grow very poorly in vitro unless supplemented with bone marrow stromal cells or exogenous cytokines. Cytokines such as interleukin-7 (IL-7) or IL-2 produced by bone marrow stromal cells and which signal through the common γ-chain receptor are contributing to the survival and proliferation of leukemic blasts. [2] [3] [4] We have recently reported that a Ras activator, RasGRP1, cooperates with cytokines to drive leukemogenesis in T-ALL, highlighting RasGRP1 as one critical component. 5 RasGRP1 belongs to the RasGRP (Ras guanine nucleotidereleasing protein) family of proteins that act as nucleotide exchange factors for Ras (reviewed in Ksionda et al. 6 ). RasGRP1 expression is best described in immune cells: it is highly abundant in T cells and to lesser extent in B, NK and mast cells. RasGRP1 is critical in the regulation of thymocytes as RasGRP1-deficient mice exhibit a profound T-cell developmental block, 7 whereas dysregulation of RasGRP1 expression leads to T-ALL in various mouse models and is frequently observed in pediatric T-ALL patients. 5, 6, [8] [9] [10] The molecular connections between cytokine receptors, RasGRP1, and downstream effectors in the Ras pathway have remained undefined.
The canonical RasGRP1-Ras signaling pathway has been best studied in the context of T-cell receptor (TCR) stimulation. In short, TCR crosslinking results in the activation of a signaling cascade involving several kinases (namely, Lck and Zap70) and assembly of a signaling complex containing the adaptor molecule LAT. LAT has several tyrosine sites, which serve as docking sites for phospholipase C-γ1 (PLCγ1), among other molecules. Upon activation, PLCγ1 converts membrane-bound phosphatidylinositolbisphosphate to release two secondary messengers: diacylglycerol (DAG) and inositol-triphosphate. Inositol-triphosphate initiates cytoplasmic calcium flux (reviewed in Feske et al. 11 ), whereas DAG recruits RasGRP1 to the membrane via binding to the C1 domain of RasGRP1 and recruits members of protein kinase C kinase family, notably protein kinase Cθ, which can phosphorylate RasGRP1 to further enhance its function to catalyze GDP to GTP exchange on Ras (reviewed in Ksionda et al. 6 ). Our recent biophysical and cellular signaling work provided more details into the mechanisms of RasGRP1 regulation and activation. 12 RasGRP1's crystal structure revealed that this RasGEF exists in an autoinhibited, dimeric state. A calcium-induced conformational change releases RasGRP1 from its autoinhibition and allows for binding of the C1 domain to DAG and for binding of Ras to RasGRP1's catalytic pocket. Our insights from the RasGRP1 structure, RasGRP1's overexpression in T-ALL and the novel RasGRP1-dependent cytokine-induced Ras activation recently identified in T-ALL 5 inspired us to investigate the mechanism of RasGRP1-Ras signals in cytokineresponsive T-ALL.
RESULTS
Cytokine-induced Ras activation is unique to T-ALL T-ALL cell lines with high RasGRP1 expression robustly activate Ras when stimulated with cytokines in a RasGRP1-dependent manner, 5 pointing to a potential cytokine receptor-RasGRP1-Ras pathway. To compare directly the effects of TCR versus cytokine stimulation on Ras activation, we stimulated two T-ALL lines (1156S-O and T-ALL C6 cell lines) that express high levels of RasGRP1 5 by either crosslinking CD3 and CD4 (TCR stimulation) or by exposure to a cocktail of IL-2, -7 and -9 (cytokine stimulation; ILs) and subjected cells to RasGTP pulldown assays. Both types of stimuli demonstrated roughly similar increases in RasGTP levels when analyzed side by side (Figures 1a and b) . As comparison, we subjected a different T-ALL cell line (98) to the same assay. T-ALL line 98 does not overexpress RasGRP1 nor has it any leukemia virus insertions in genes that are known to influence the Ras pathway. 5 As shown in Figure 1c , T-ALL 98 cells do accumulate some RasGTP upon IL stimulation, albeit to much lesser extent as lines that overexpress RasGRP1.
Based on cell surface marker expression, T-ALL blasts resemble developing thymocytes.
1,5 Therefore, we next investigated if normal thymocytes also use the IL-RasGRP1-Ras pathway. In contrast to our T-ALL cell lines, ex vivo thymocytes activated Ras after TCR stimulation but not following exposure to cytokines (Figure 1d ). Signal transducer and activator of transcription 5 phosphorylation (pSTAT5), a well-characterized signal induced by cytokine receptors containing the common γ-chain, is shown here as a positive control to demonstrate proper IL-2/7/9 stimulation of thymocytes ( Figure 1d ). Therefore, T-ALL cells with RasGRP1 overexpression-and cell surface marker combinations reminiscent of developing thymocytes-have the unique ability to activate Ras in response to cytokine receptor stimulation ( Figure 1e ). (e) Scheme depicting activation of TCR-RasGRP1-Ras pathway in thymocytes and T-ALL cells as well as IL-RasGRP1-Ras, which in contrast to the first pathway seems to be unique to T-ALLs.
Distinct, RasGRP-1-dependent signals through the Akt pathway in cytokine-stimulated T-ALL RasGTP signals to various effector kinase pathways to exert its cell biological effect on survival and proliferation. 13 To compare effector activation following ILR-RasGRP1 versus 'canonical' TCR-RasGRP1 signals, we exposed T-ALLs with high RasGRP1 to each of the stimuli and examined the activation status of two well-characterized Ras effectors, Erk1/2 and PI3K. TCR stimulation resulted in transient Erk1/2 and sustained Akt phosphorylation (phospho-Akt serving as a surrogate for PI3K activation) in T-ALLs (Figure 2a ). Cytokines (IL-2, -7 and -9) activated the PI3K/Akt pathway in T-ALL cells to a similar degree as TCR stimulation, whereas activity through the RasGTP-Raf-MEK-Erk pathway was modest ( Figure 2b ). As before, phosphorylation of STAT5 was measured as a positive control for IL stimulation (Figure 2b) .
Given that cytokines appear to preferentially trigger Ras-PI3K/ Akt over Ras-Raf-MEK-Erk pathway in T-ALL, we sought to explore if TCR and IL-induced Akt activation depends on RasGRP1. We took advantage of previously generated cell lines with reduced RasGRP1 levels via stable expression of RasGRP1 short hairpin RNA (shRNA). 5 Knockdown of RasGRP1 severely impairs both TCR-and IL-induced Akt phosphorylation without affecting cytokinedepending pSTAT5 levels (Figures 2c and d, respectively) , revealing that activation of PI3K/Akt downstream of both receptor systems depends on RasGRP1.
Our RasGTP pulldown assay (Figure 1d ) indicated that the IL-RasGRP1-Ras pathway is not functional in normal thymocytes. Thymocytes consist of four major subsets that reflect unique developmental stages and which differ in the expression levels of cytokine receptors (immgen.org). It is possible that only a minor population of cells activates Ras and Ras effector pathways downstream of cytokine receptors and that this signal is missed because of the detection limitations of the experimental method that assays population averages. To overcome these limitations and to confirm that normal thymocytes do not activate Ras and its effectors downstream of cytokine receptors, we took advantage of flow cytometry. Flow cytometric analysis of signaling events induced by TCR stimulation, similar to ERK phosphorylation, has been used by many groups including our own. 14 (Figure 2e , bottom panel). We then looked at the activation of pErk1/2 and pAkt as a surrogate measure of Ras activity. We did not observe increases in pErk or pAkt upon cytokine stimulation in any of the subsets, suggesting that Ras is not activated after cytokine receptor activation by IL-2/7/9 in normal thymocytes ( Figure 2e , top and middle panel). All thymic populations increased pErk1/2 in response to phorbol myristate acetate stimulation (Figure 2e , top panel, blue histogram), which demonstrated that the lack of pErk induction after cytokine exposure was not due to technical inability to detect pErk. Thus, both TCR-and ILR-triggered Ras effector pathways are operational in T-ALL cells, but cytokine stimulation triggers Akt activation more robustly than Erk activation and does so in a RasGRP1-dependent manner (Figure 2f ). Based on these results, we hypothesized that mechanisms of RasGRP1-driven Ras activation may differ between TCR-and cytokine-stimulated T-ALL cells.
Cytokine receptor-RasGRP1-Ras signaling does not require acute PLCγ1 activation We next sought to explore if RasGRP1 couples to cytokine receptors in leukemic T-ALL via PLCγ1 as it does in canonical RasGRP1-Ras signaling induced by TCR stimulation. Pharmacological inhibition of PLCγ with a small-molecule inhibitor U73122 resulted in a profound decrease in RasGTP, confirming that TCR-induced RasGTP in T-ALL cells indeed depends on PLCγ1 activity (Figure 3a ). In agreement with canonical RasGRP1 signaling, TCR stimulation resulted in induction of both PLCγ1 and RasGRP1 phosphorylation in T-ALL cells (Figure 3b ) and TCR-induced RasGRP1 phosphorylation was decreased following PLCγ inhibitor treatment (Figure 3c ).
We next asked if similar second messengers connect RasGRP1 and cytokine receptors. In contrast to TCR stimulation where PLCγ inhibitor treatment almost completely abrogated RasGTP induction, we observed only a modest effect of the PLCγ inhibitor on cytokine-induced RasGTP (Figure 3d and Supplementary  Figure 2) . Consistent with the reduced requirement for acute PLCγ1 activation, cytokine treatment did not increase PLCγ1 or RasGRP1 phosphorylation above baseline levels in either of two T-ALL cell lines tested ( Figure 3e ). Also, pharmacological inhibition of PLCγ1 showed no effect on RasGRP1 phosphorylation following cytokine stimulation ( Figure 3f ). Of note, we avoided further increasing the concentration of the PLCγ inhibitor or extending the incubation time before stimulation, as these induced nonspecific cell toxicity.
The above data suggest that cytokines do not couple to PLCγ1; however, phosphorylation of PLCγ1 is only a surrogate for activation rather than a direct measurement of activity. To test more definitively that cytokine receptors do not induce PLCγ1 enzymatic activity in T-ALL cells, we evaluated rises in intracellular calcium as a direct effect of inositol-triphosphate production, which is a routine assay used by many to determine TCR-triggered calcium fluxes. Consistent with the data in Figures 3d and f, we did not observe any detectable increase in calcium levels upon cytokine stimulation, even within 10 min of recording ( Figure 3g , red tracing), whereas TCR stimulation resulted in a rapid rise in intracellular calcium (Figure 3g ; blue tracing). Taken together, these data demonstrate that while RasGRP1-overexpressing T-ALL cells maintain the ability to respond to TCR stimulation that requires PLCγ1 activation, the IL-RasGRP1-Ras pathway does not require receptor-induced PLCγ1 activity.
RasGRP1 couples to the cytokine receptor via basal DAG Binding of calcium to the EF hands of the RasGRP1 protein releases autoinhibition through allosteric changes.
12 NMR scattering data indicates that autoinhibition of this RasGEF is not absolute and that there is some level of flexibility in the basal state without calcium signals 12 ( Figure 4a , left panel). These structural aspects together with our observations that basal, low-level PLCγ1 and RasGRP1 phosphorylation can be detected in T-ALL cells (Figure 3e ) prompted us to hypothesize that basal levels of DAG are sufficient for RasGRP1-dependent Ras activation in cytokine-stimulated T-ALL cells. To test this hypothesis, we used the DAG kinase (DGK) inhibitor R59945 to manipulate DAG levels without changing Ca 2+ levels ( Figure 4a , right panel). DGKs convert DAG to phosphatidic acid and pharmacological inhibition of DGK results in increased DAG levels 15 and increased RasGTP in response to TCR stimulation. 16 Treatment of T-ALL cells with DGK inhibitor (R59945) resulted in a dose-dependent induction of pAkt and pErk signals, in complete absence of cytokine receptor or other stimulatory input (Figures 4b and c) . These findings are consistent with our previous mathematical modeling, which predicted that in the presence of high RasGRP1 concentration increasing DAG levels result in spontaneous Ras pathway activation. 5 These results also reveal that overexpressed RasGRP1 couples to Ras in the basal state, without the requirement for receptor signals.
We subsequently asked if increased levels of baseline DAG could enhance cytokine-induced Ras effector activation. Indeed, we observed that cytokine-induced pAkt was increased after augmenting concentrations of DAG by treatment with DGK inhibitor (Figure 4d ). Last, we investigated if low levels of cytokine input cooperates with increased baseline DAG levels and determined that R59945 concentrations as low as 100 nM potentiated cytokine-induced pAkt (Figure 4e ). Taken together, these results indicate that when expressed at high levels, similar to a subset of T-ALL leukemias, 5 RasGRP1 responds to baseline cellular levels of DAG to activate Ras effector pathways, which can be further induced by cytokine stimulation. Figures 3 and 4 demonstrate that RasGRP1 couples to basal DAG, one would predict that T-ALL cells with RasGRP1 overexpression efficiently accumulate RasGTP in the unstimulated state. However, we previously established that RasGRP1 T-ALLs display only very modest increases in the basal levels of RasGTP. This contrasted the high levels of baseline RasGTP observed in T-ALL with oncogenic Ras mutations (such as KRas G12D ) that render Ras protein insensitive to GAP action. 5 Net RasGTP levels are the sum of GTP loading and GTP hydrolysis. We postulated that T-ALLs may contain high steady-state RasGAP activity to counteract the increased RasGRP1 activity in resting cells. To gain more insight into this equilibrium, we first looked at the expression of the two best characterized RasGAPs, NF1 and p120RasGAP. In a panel of 11 human T-ALL cell lines, all cell lines expressed both NF1 and p120RasGAP at roughly similar levels as determined by western blot analysis (Figure 5a ). The Jurkat T-cell lymphoma and JPRM441 cell line, a Jurkat derivate expressing only 10% of normal RasGRP1 levels, 17 revealed similar NF1 and p120RasGAP levels (Figure 5a ), indicating that RasGRP1 does not influence expression levels of these RasGAPs.
Broad coverage of expressed RasGAP molecules in T-ALL Given that our experiments in
We reported that RasGRP1 reveals a large 128-fold range in mRNA expression levels among 107 primary T-ALL samples of pediatric patients. 5 Here, we plotted mRNA levels for 10 RasGAP family members reported to be expressed in lymphocytes (King et al., 18 immgen.org) from the same microarray data of 107 T-ALL patients. We were struck to find that the primary samples expressed all RasGAP family members with only relatively small variations in mRNA expression between patients (Figure 5b) . Additionally, expression of individual RasGAPs did not correlate with clinical outcome (Supplementary Figure 1) . Given the above expression data and the critical biologic importance of tight regulation of RasGTP levels in cells, the regulation of the 
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Increased RasGRP1 levels lead to high rate of flux through RasGDP/RasGTP cycle To investigate directly the equilibrium between RasGDP/GTP and the equilibrium between RasGEF and RasGAP activity in the setting of RasGRP1 overexpression, we compared and contrasted three distinct Ras assays. First, we expanded on our published data with the traditional RasGTP pulldown assay, confirming that increased RasGRP1 expression does not result in high levels of RasGTP in the basal state, especially when compared with T-ALL cell lines that harbor KRas G12D mutation (Figures 6a). 5 However, the pulldown assay does not provide any insights regarding the rate of RasGTP/GDP cycling (Figure 6a ). To gain insight into the latter, we took advantage of a Ras nucleotide exchange assay 19 to evaluate the rate of GTP loading (Figure 6b) . Briefly, cells are permeabilized with digitonin to allow entry of radioactive α-phosphate-labeled GTP. This radiolabeled GTP is loaded onto Ras and can be hydrolyzed into RasGDP without loss of the radiolabeled nucleotide. Cells are lysed and Ras-bound radionucleotide is quantified and represents the amount of GTP loaded onto Ras as a function of time (Figure 6b ).
We first investigated loading of GTP into Ras in three nonimmune cell lines (Cos7, Rat1 and HeLa), which lack or express low levels of RasGRP exchange factors. 17, 20, 21 In agreement with previously reported data for Cos7 cells, 21 all three cell lines show a slow rate of GTP loading and never reached plateau within the experimental time frame (Figure 6c ). In contrast, in immune cells radioactivity levels quickly increased and were saturated at roughly 2 min, indicating that all Ras molecules had experienced one round of nucleotide exchange. This result confirms previous findings for T cells 22, 23 and suggests that immune cells that express RasGRP family members (RasGRP4 in U937 and RasGRP1 in Jurkat and human primary T cells; Roose et al. 17 ) have exceptionally high basal rates of nucleotide exchange on Ras (some 30-fold higher than the intrinsic exchange rate of Ras 24 ) (Figure 6d ).
Focusing selectively on overexpression of RasGRP1 in leukemia, we find the rapid GTP loading in the Jurkat T-cell lymphoma line is dependent on this RasGEF as the rate of radionucleotide loading is significantly decreased in RasGRP1-deficient JPRM441 cells (Figure 6e Figure 6e , stable knockdown of RasGRP1 in the 1156S-O T-ALL line caused a marked reduction of nucleotide uptake by Ras that was not seen in the GFP control 1156S-O line, confirming that basal GTP loading of Ras in these T-ALL lines was driven by RasGRP1. Collectively, these data demonstrate that high levels of RasGRP1 expression in T-ALL cells lead to constitutively high nucleotide exchange rates on Ras.
These data again argue for equally high basal RasGAP activity in T-ALLs with RasGRP1 overexpression, given the minimally increased steady-state levels of RasGTP. As a third assay, we combined the permeabilization approach with the RasGTP pulldown assay. We reasoned that loading T cells with the nonhydrolyzable GTP analog GMppNHp should promote Ras activation solely via nucleotide exchange because RasGAP activity is futile against Ras-GMppNHp. As shown in Figure 6f , Jurkat cells permeabilized in the presence of GTP featured higher RasGTP levels compared with the low-RasGRP1 derivative JPRM441, in accordance with the notion that basal nucleotide uptake by Ras, as driven by RasGRP1, is a prerequisite for the accumulation of RasGTP. Importantly, when permeabilized in the presence of the non-hydrolyzable GTP analog, GMppNHp-active Ras accumulation rose markedly in Jurkat and also, albeit to a lesser extent, in JPRM441s. Although GMppNHp is certainly likely to affect the activity of other G proteins in the T cells, the simplest interpretation of these data was that resting T-ALL cells harbor high RasGAP activity, which is needed to balance the equally high basal nucleotide exchange on Ras driven by RasGRP1.
DISCUSSION
We demonstrate that the cytokine receptor-RasGRP1-Ras pathway is unique to T-ALL that overexpress RasGRP1, a feature observed in approximately half of pediatric T-ALL patients. 5 We also provide evidence that dysregulated RasGRP1 uses basal DAG to anchor to the membrane, is already phosphorylated and therefore 'primed' to facilitate GDP/GTP exchange on Ras. In agreement, we uncovered constitutively high levels of GTP loading on to Ras that occurs exclusively in the setting of RasGRP1 overexpression.
Analysis of Ras effectors revealed that in cytokine-stimulated T-ALL, PI3K-Akt signals were more robustly induced than MEK/Erk. Interestingly, we observed a strong reduction in pAkt levels in T-ALL cell lines with RasGRP1 knockdown, and this effect was much more pronounced than previously reported in thymocytes (Figures 2c and d) . 25 The molecular mechanism for this differential sensitivity of pAkt compared with pErk is unknown. PI3K but not MEK is important for viability and cell cycle progression of T-ALL blasts. 26 Our observation that RasGRP1 preferentially couples to PI3K-Akt signals combined with the fact that RasGRP1 is not ubiquitously expressed suggest that targeting RasGRP1 may prove to be an effective way to dampen PI3K signals in leukemic cells.
The collective results of our three distinct Ras assays reveal rapid nucleotide loading of GTP into Ras in T-ALL with RasGRP1 overexpression, suggesting that even without receptor input RasGRP1 can exert its function and the protein must 'breathe' enough to be released from its autoinhibited state and use cellular DAG and Ca 2+ for full activation (Figure 6e ). Based on mathematical modeling one consequence of high flux through RasGDP/GTP cycle at basal state would be much faster accumulation of RasGTP after receptor triggering as compared with the settings with low basal flux. 24 In light of our experimental observations, we have proposed a model in which high loading of GTP into Ras by RasGRP1 is counterbalanced by RasGAP-mediated hydrolysis to keep RasGTP levels low under resting conditions (Figure 6g ). Given that we found no evidence of cytokine-induced RasGRP1 activation (Figure 3e ), it is a logical possibility that cytokines decrease RasGAP activity in the leukemic cell, ultimately resulting in RasGTP accumulation (Figures 1a and b and Figure 6g ). It is possible that other receptor systems such as granulocyte-colony-stimulating factor or granulocyte-macrophage colony-stimulating factor (reviewed in Ksionda et al. 6 ) cooperate with RasGRP signaling in a similar manner. This mode of GTPase activation, that is, via receptor-induced inactivation of GAP, has been recently shown for Rheb, a Ras-related GTPase, and some evidence points out that it may also be the case for Ras (reviewed in Hennig et al. 24 and Laplante and Sabatini 27 ). It has previously been shown that certain growth factors such as platelet-derived growth factor or epidermal RasGRP1 overexpression in T-ALL O Ksionda et al growth factor induce proteolytic degradation of NF1, one of the RasGAPs. 28 However, we did not observe any change in levels of NF1 or P120RasGAP after cytokine stimulation. Given that T-ALL cells express many RasGAPs (Figure 5 ), dissecting the mechanisms involved in both basal regulation of RasGTP/GDP and cytokine receptor action in transformed lymphocytes will require new genetic tools such as combination T-cell-specific knockout mice for RasGAPs or CRISPR/cas9-mediated cell line models.
Our results strongly point to a role of RasGAPs as crucial safeguards, especially in leukemic cells with dysregulated expression of RasGRP1. The mutational status of all RasGAPs has not been explored in the context of T-ALL, but our results show that at least 10 RasGAP family members are expressed in each of the pediatric T-ALL samples analyzed ( Figure 5 ). It appears that broad coverage with different RasGAP proteins is required to counterbalance Ras nucleotide loading. This idea is supported by studies showing that T-lineage knockouts of NF1 or p120RasGAP had only minor phenotype and did not result in T-ALL, 29, 30 but that their combined deletion leads to the development of T-ALL. 31 The importance of RasGAPs is also highlighted by emerging data showing that NF1 is mutated in both pediatric and adult T-ALL patients. [32] [33] [34] Interestingly, there seems to be an increased instability of the Ras network evidenced by increased co-occurrence of NF1 mutations with other RasGAPs or RasGEFs in a wide range of human cancers. 35 It would be interesting to investigate whether high basal RasGRP1 activity would lead to increased instability of the Ras network in T-ALL.
In summary, our findings document that overexpression of RasGRP1 in a subset of T-ALLs effectively renders Ras and Ras effector pathways in these leukemias responsive to pro-oncogenic cytokines. We propose that overexpression of RasGRP1 and the resulting high nucleotide exchange on Ras essentially create a new signaling avenue for proleukemic cytokines that can provide pro-oncogenic Ras signals in T-ALL. It is intriguing to speculate that similar scenarios may apply to other Ras-dependent tumors. For example, EGFR overexpression, as present in numerous solid cancers, might work in an analogous manner to high RasGRP1 levels in leukemia to drive basal nucleotide exchange on Ras 36, 37 and to render Ras pathways in those cancers overresponsive to alternate mitogenic factors.
MATERIALS AND METHODS
Cell lines
Murine T-ALL cell lines (1156S-O, 1156S-O-shRNA RasGRP1, 1156S-O-GFP, 1713S-N, T-ALL C6, T-ALL 9, T-ALL 15, T-ALL 55 and 98) were originally generated and maintained as described in Hartzell et al. 5 Human T-ALL cell lines were cultured in RPMI 10% fetal bovine serum, penicillin and streptomycin.
Antibodies
The following antibodies were used in this study: phospho-Akt (S473) (Cell Signaling, Danvers, MA, USA; No. 4060), phospho-Erk1/2 (T202/Y204) (Cell Signaling; no. 4377), phospho-STAT5 (Y694) (Cell Signaling; no. 9351), phospho-PLCγ1 (Y783) (Invitrogen, Waltham, MA, USA; 44-696G), α-tubulin (Sigma, St Louis, MO, USA; T6074), total Ras (clone RAS10) (Millipore, Billerica, MA, USA; 05-516), neurofibromin (NF1) (Santa Cruz Biotechnologies, Dallas, TX, USA; sc-67), p120RasGAP (BD Biosciences, San Jose CA, USA; 610040), anti-CD4 (GK1.5) (Alexa Fluor 488; eBiosciences, San Diego, CA, USA), CD8 (53-6.7) PerCP Cy5.5 (BD Biosciences), TCRβ (H57-597) (APC Biolegends, San Diego, CA, USA), and donkey anti-rabbit PE (711-116-152) and donkey anti-rabbit APC (711-136-152) from Jackson ImmunoResearch (West Grove, PA, USA). Murine RasGRP1 (m199) antibody was a gift from Dr Jim Stone. To detect phospho-RasGRP1 (T184), we generated an antibody against epitope SRKL-pT-QRIKSNTC. This mouse monoclonal antibody (clone 4G7) was generated and purified by AnaSpec (Fremont, CA, USA).
In vitro stimulations, Ras pulldown and western blotting Cells were washed and rested in phosphate-buffered saline at 37°C for 30 min before stimulation. Where indicated, cells were treated with dimethyl sulfoxide (DMSO) or inhibitors (PLCγ inhibitor U73122; Calbiochem, San Diego, CA, USA; 662035; DGK inhibitor; Sigma; D5794) during resting. After resting, cells were stimulated with anti-CD3/anti-CD4 (each 10 μg/ml) followed by goat anti-hamster (10 μg/ml) and goat anti-rat antibodies (1/1000), cytokines: IL-2, IL-7, IL-9 (each at 10 ng/ml, unless otherwise noted; Peprotech, Rocky Hill, NJ, USA) or phorbol myristate acetate (25 ng/ml). All other techniques were described previously. 5 Flow cytometry and fluorescent barcoding.
Stainings were carried out in FACS buffer containing phosphate-buffered saline without calcium and magnesium salts (phosphate-buffered saline CMF) supplemented with 2% fetal calf serum, 2 mM EDTA and 0.09% NaN 3 . Where surface staining was combined with intracellular staining, the following protocol was followed: cells were fixed with 2% paraformaldehyde for 20 min at room temperature (RT). Cells were washed three times with FACS buffer and permeabilized with 90% ice-cold methanol for 30 min at 4°C. After washing, cells were incubated with antibodies specific for phosphoproteins for 1 h at RT followed by washing and incubation for 30 min at RT with secondary antibodies and antibodies against surface markers. If samples were barcoded, fluorescent dyes (Alexa Fluor 488 carboxylic acid, succinimidyl ester; Molecular Probes (Eugene, OR, USA); A-20000; or Pacific Blue succinimidyl ester; Molecular Probes; P-10163) were added to methanol and permeabilization took place at RT as described. 38 Samples were acquired on BD LSR II (Franklin Lakes, NJ, USA) and analyzed with FlowJo (Ashland, OR, USA) or Cytobank (Mountain View, CA, USA).
Calcium flux measurements Cells were washed with IMDM (Iscove's modified Dulbecco's medium) without serum and loaded with 2 μg/ml of the Ca 2+ indicator Indo-1 (Molecular Probes; I1223) for 40 min at 37°C. Subsequently, cells were washed and resuspended in IMDM medium. For calcium flux measurements via flow cytometery, cells were stimulated with anti-CD3 antibody (2C11, 10 μg/ml) and a baseline was registered for 20 s, then a crosslinking antibody (goat anti-hamster immunoglobulin G; final concentration 2 μg/ml) or cytokines were added and calcium levels were measured and analyzed on as LSR II flow cytometer (BD Biosciences).
Gene expression analysis in pediatric T-ALL patients
Patient sample collection and RasGAP expression analysis was performed as described previously. 5 In all cases, except RASAL3, multiple probe sets were identified for the gene of interest. Data were normalized using RMA (robust multiarray average). 
